Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Anesthetics Local/*therapeutic use *Cystoscopy Humans Lidocaine/*therapeutic use Male Pain Management/*methods Pain Measurement Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/diagnosis/therapy administration cystoscopy intravesical lidocaine pain procedural urinary bladder neoplasms

Carcinoma Transitional Cell/diagnosis/epidemiology/*therapy Child Combined Modality Therapy *Disease Management Disease Progression Global Health Humans Incidence Risk Factors Survival Rate/trends Urinary Bladder/*pathology Urinary Bladder Neoplasms/diagnosis/epidemiology/*therapy Management Pediatric Surveillance Transurethral resection Urothelial cell carcinoma

Biopsy/methods Carcinoma in Situ/*pathology/*therapy Humans Muscle Smooth Neoplasm Invasiveness Urinary Bladder Neoplasms/*pathology/therapy Biopsias aleatorias de vejiga Carcinoma in situ Non-muscle invasive bladder cancer Random bladder biopsies Tumor vesical no-músculo invasivo